Luxembourg Parkinson's study -comprehensive baseline analysis of Parkinson's disease and atypical parkinsonism

Lukas Pavelka; Rajesh Rawal; Soumyabrata Ghosh; Claire Pauly; Laure Pauly; Anne-Marie Hanff; Pierre Luc Kolber; Sonja R Jónsdóttir; Deborah Mcintyre; Kheira Azaiz; Elodie Thiry; Liliana Vilasboas; Ekaterina Soboleva; Marijus Giraitis; Olena Tsurkalenko; Stefano Sapienza; Nico Diederich; Jochen Klucken; Enrico Glaab; Gloria A Aguayo; Eduardo Rosales Jubal; Magali Perquin; Michel Vaillant; Patrick May; Manon Gantenbein; Venkata P Satagopam; Rejko Krüger; NCER-PD Consortium

doi:10.3389/fneur.2023.1330321

Luxembourg Parkinson's study -comprehensive baseline analysis of Parkinson's disease and atypical parkinsonism

Front Neurol. 2023 Dec 19:14:1330321. doi: 10.3389/fneur.2023.1330321. eCollection 2023.

Authors

Lukas Pavelka^#^{1

2

3}, Rajesh Rawal^#⁴, Soumyabrata Ghosh⁴, Claire Pauly^{1

2

3}, Laure Pauly^{1

2

3

5}, Anne-Marie Hanff^{1

5

6}, Pierre Luc Kolber^{2

7}, Sonja R Jónsdóttir^{1

2

3}, Deborah Mcintyre^{1

2}, Kheira Azaiz^{2

3}, Elodie Thiry^{2

3}, Liliana Vilasboas^{2

3}, Ekaterina Soboleva^{2

3}, Marijus Giraitis⁸, Olena Tsurkalenko⁸, Stefano Sapienza⁸, Nico Diederich⁷, Jochen Klucken⁸, Enrico Glaab⁹, Gloria A Aguayo¹⁰, Eduardo Rosales Jubal¹¹, Magali Perquin⁸, Michel Vaillant¹¹, Patrick May⁴, Manon Gantenbein¹¹, Venkata P Satagopam⁴, Rejko Krüger^{1

2

3}; NCER-PD Consortium

Affiliations

¹ Transversal Translational Medicine, Luxembourg Institute of Health (LIH), Strassen, Luxembourg.
² Parkinson Research Clinic, Centre Hospitalier de Luxembourg (CHL), Strassen, Luxembourg.
³ Translational Neuroscience, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.
⁴ Bioinformatics Core, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.
⁵ Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
⁶ Department of Epidemiology, CAPHRI School for Public Health and Primary Care, Maastricht University Medical Centre, Maastricht, Netherlands.
⁷ Department of Neurosciences, Centre Hospitalier de Luxembourg (CHL), Strassen, Luxembourg.
⁸ Department of Precision Health, Luxembourg Institute of Health (LIH), Strassen, Luxembourg.
⁹ Biomedical Data Science Group, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.
¹⁰ Deep Digital Phenotyping Research Unit, Luxembourg Institute of Health (LIH), Strassen, Luxembourg.
¹¹ Translational Medicine Operations Hub, Luxembourg Institute of Health (LIH), Strassen, Luxembourg.

^# Contributed equally.

Abstract

Background: Deep phenotyping of Parkinson's disease (PD) is essential to investigate this fastest-growing neurodegenerative disorder. Since 2015, over 800 individuals with PD and atypical parkinsonism along with more than 800 control subjects have been recruited in the frame of the observational, monocentric, nation-wide, longitudinal-prospective Luxembourg Parkinson's study.

Objective: To profile the baseline dataset and to explore risk factors, comorbidities and clinical profiles associated with PD, atypical parkinsonism and controls.

Methods: Epidemiological and clinical characteristics of all 1,648 participants divided in disease and control groups were investigated. Then, a cross-sectional group comparison was performed between the three largest groups: PD, progressive supranuclear palsy (PSP) and controls. Subsequently, multiple linear and logistic regression models were fitted adjusting for confounders.

Results: The mean (SD) age at onset (AAO) of PD was 62.3 (11.8) years with 15% early onset (AAO < 50 years), mean disease duration 4.90 (5.16) years, male sex 66.5% and mean MDS-UPDRS III 35.2 (16.3). For PSP, the respective values were: 67.6 (8.2) years, all PSP with AAO > 50 years, 2.80 (2.62) years, 62.7% and 53.3 (19.5). The highest frequency of hyposmia was detected in PD followed by PSP and controls (72.9%; 53.2%; 14.7%), challenging the use of hyposmia as discriminating feature in PD vs. PSP. Alcohol abstinence was significantly higher in PD than controls (17.6 vs. 12.9%, p = 0.003).

Conclusion: Luxembourg Parkinson's study constitutes a valuable resource to strengthen the understanding of complex traits in the aforementioned neurodegenerative disorders. It corroborated several previously observed clinical profiles, and provided insight on frequency of hyposmia in PSP and dietary habits, such as alcohol abstinence in PD.Clinical trial registration: clinicaltrials.gov, NCT05266872.

Keywords: Parkinson’s disease; REM-sleep behaviour disorder; environment exposure; hyposmia; parkinsonian disorders; progressive supranuclear palsy.

Copyright © 2023 Pavelka, Rawal, Ghosh, Pauly, Pauly, Hanff, Kolber, Jónsdóttir, Mcintyre, Azaiz, Thiry, Vilasboas, Soboleva, Giraitis, Tsurkalenko, Sapienza, Diederich, Klucken, Glaab, Aguayo, Jubal, Perquin, Vaillant, May, Gantenbein, Satagopam, Krüger and on behalf of the NCER-PD Consortium.

Associated data

ClinicalTrials.gov/NCT05266872

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by grants from the Luxembourg National Research Fund (FNR) within the National Centre of Excellence in Research in Parkinson’s disease [NCER- PD; (FNR/NCER13/BM/11264123)] and the PEARL programme (FNR; FNR/P13/6682797 to RK) as well as by the European Union’s Horizon 2020 research and innovation program under Grant Agreement No. 692320 (WIDESPREAD; CENTRE-PD; Grant Agreement No. 692320; CENTRE-PD to RK); dHealthPD PEARL programme to JK (14146272); DIGIPD (ERAPERMED 2020-314) to EG, RECAST (INTER/22/17104370) to EG.